CD8A and neoplasm: To sum up, confirmatory multicenter approaches, including higher volumes of patients for each tumor entity and ICI agent, possibly combining even more immunological components of the cancer patient network (CPN), therapeutic modalities and mechanistic approaches are warranted, so that sLAG3, CD4/CD8 ratio and their combined immunological score can be assessed to gain deeper knowledge into the predictive role of these molecules.